Walleye Trading’s BridgeBio Pharma BBIO Stock Holding History

Walleye Trading’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$193K	Sell	2,600 -12,200	-82%	-$884K	﹤0.01%	3143
2025 Q4	$1.13M	Buy	14,800 +8,800	+147%	+$578K	﹤0.01%	2280
2025 Q3	$312K	Sell	6,000 -200	-3%	-$9.76K	﹤0.01%	3079
2025 Q2	$268K	Buy	6,200 +300	+5%	+$10.9K	﹤0.01%	3053
2025 Q1	$204K	Sell	5,900 -41,100	-87%	-$1.39M	﹤0.01%	3073
2024 Q4	$1.29M	Buy	+47,000	New	+$1.21M	﹤0.01%	1983
2024 Q2	–	Sell	-10,800	Closed	-$334K	–	4289
2024 Q1	$334K	Buy	10,800 +7,300	+209%	+$248K	﹤0.01%	3107
2023 Q4	$141K	Sell	3,500 -4,600	-57%	-$138K	﹤0.01%	3985
2023 Q3	$214K	Buy	8,100 +7,700	+1,925%	+$219K	﹤0.01%	3559
2023 Q2	$6.88K	Sell	400 -6,000	-94%	-$90.3K	﹤0.01%	4307
2023 Q1	$106K	Buy	+6,400	New	+$74.6K	﹤0.01%	3825
2022 Q3	–	Sell	-17,900	Closed	-$163K	–	5040
2022 Q2	$163K	Sell	17,900 -7,800	-30%	-$65.2K	﹤0.01%	3841
2022 Q1	$261K	Buy	+25,700	New	+$264K	﹤0.01%	3562

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Trading's BBIO Position: Q1 2026 in Review

Walleye Trading reduced its BridgeBio Pharma (BBIO) stake by 58% in Q1 2026, selling an estimated $173K and leaving 1,745 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #3336.

Walleye Trading first reported a position in BBIO in Q1 2021 and has held it in 11 quarters since. The position peaked at $489K in Q2 2023. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Walleye Trading held 1,745 shares of BridgeBio Pharma worth $130K as of Q1 2026.
Walleye Trading sold 2,386 BridgeBio Pharma shares in Q1 2026, an estimated $173K.
BridgeBio Pharma made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #3336 holding.
Walleye Trading first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 11 quarters since.
Walleye Trading's BridgeBio Pharma position peaked at $489K in Q2 2023.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.